Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barry Greene Insider Profile
11 Followers
Barry Greene, President at Alnylam Pharma, holds 46.94K shares in SAGE Therapeutics (Ticker: SAGE), holds 13.61K shares in Karyopharm Therapeutics (Ticker: KPTI), holds 73.50K shares in Alnylam Pharma (Ticker: ALNY). Most recently, Barry Greene Bought ― shares of SAGE Therapeutics on Nov 15, 2022 for an estimated value of 499.96K.
Profitable Transactions
0 out of 5 Profitable Transactions
Average Return
-38.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Barry Greene holds in companies
Most Profitable Insider Trade
The most profitable trade made by Barry Greene
Barry Greene's Trading History
Alnylam Pharma
Sep 11, 2020
President
Uninformative Buy
859.24K
$17.26M
SAGE Therapeutics
Nov 15, 2022
President & CEO, Director
Informative Buy
499.96K
$515.87K
Karyopharm Therapeutics
Aug 15, 2022
Director
Uninformative Buy
11.21K
$13.20K
Acorda Therapeutics
May 23, 2018
Director
Uninformative Buy
25.66K
$92.93
Regulus
Oct 11, 2012
Director, Ten Percent Owner
Uninformative Buy
―
$10.95M
List of latest transactions for each holding click on a transaction to see Barry Greene's performance on stock
You May Also Like
Barry Greene insider profile FAQ
What is the percentage of profitable transactions made by Barry Greene?
The percentage of profitable transactions made by Barry Greene is 0%.
What is the average return per transaction made by Barry Greene?
The average return per transaction made by Barry Greene is -38.10%.
What stocks does Barry Greene hold?
Barry Greene holds: ALNY, SAGE, KPTI, ACORQ, RGLS stocks.
What was Barry Greene’s latest transaction?
Barry Greene latest transaction was an Informative Buy of $499.96K.
What was Barry Greene's most profitable transaction?
Barry Greene’s most profitable transaction was an Informative Buy of SAGE stock on August 9, 2021. The return on the trade was -2.80%.
What is Barry Greene's role in Alnylam Pharma?
Barry Greene's role in Alnylam Pharma is President.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.